Table 2.
Baseline characteristics of controls, MCI and AD patients in the total group.
| Control | MCI | AD | |
|---|---|---|---|
| N | 906 | 681 | 1347 |
| Age | 62 ± 9 | 69 ± 9 | 69 ± 9a |
| Female# | 404 (45%) | 271 (40%) | 716 (53%)ab |
| MMSE | 28 ± 2 | 26 ± 2 | 20 ± 5ab |
| Level of education | 5 ± 1 | 5 ± 1 | 5 ± 1a |
| APOE e4 carrier# | 281 (36%) | 285 (54%) | 729 (54%)ab |
| MTA | 0.4 ± 0.6 | 1.0 ± 0.9 | 1.6 ± 0.9ab |
| PA | 0.6 ± 0.7 | 0.9 ± 0.7 | 1.4 ± 0.7ab |
| GCA | 0.4 ± 0.6 | 0.8 ± 0.7 | 1.2 ± 0.7ab |
| WMH | 0.7 ± 0.7 | 1.1 ± 0.9 | 1.1 ± 0.9a |
Values are mean ± standard deviation or n (%). Group differences between the different diagnostic groups were estimated using Chi-quadrate test# and Kruskal-Wallis test and post hoc Mann-Whitney U-tests when appropriate. Please note that although we report mean ± standard deviation for the visual rating scales, we used non-parametric tests.
a
P < 0.05 compared to control,
b
P < 0.05 compared to MCI.